Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Cardiff Oncology Inc (CRDF)

Cardiff Oncology Inc (CRDF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer GlobeNewswire - Fri Mar 20, 6:00AM CDT

SAN DIEGO, March 20, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

CRDF : 1.7900 (-0.56%)
Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting GlobeNewswire - Thu Mar 19, 6:00AM CDT

SAN DIEGO, March 19, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

CRDF : 1.7900 (-0.56%)
Cardiff Oncology to Participate in Three Upcoming Investor Conferences  GlobeNewswire - Thu Feb 26, 3:01PM CST

SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

CRDF : 1.7900 (-0.56%)
Cardiff Oncology: Q4 Earnings Snapshot AP - Tue Feb 24, 4:26PM CST

Cardiff Oncology: Q4 Earnings Snapshot

CRDF : 1.7900 (-0.56%)
Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update GlobeNewswire - Tue Feb 24, 3:30PM CST

Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating: • Robust ORR of 72.2% (vs 43.2% with combined SoC of...

CRDF : 1.7900 (-0.56%)
Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference GlobeNewswire - Thu Feb 19, 6:00AM CST

SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

CRDF : 1.7900 (-0.56%)
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC GlobeNewswire - Tue Jan 27, 6:05AM CST

-  Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in patients...

CRDF : 1.7900 (-0.56%)
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development GlobeNewswire - Tue Jan 27, 6:00AM CST

SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

CTMX : 4.46 (+0.22%)
CRDF : 1.7900 (-0.56%)
Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025 GlobeNewswire - Mon Dec 8, 2025

SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

CRDF : 1.7900 (-0.56%)
Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference GlobeNewswire - Mon Dec 8, 2025

SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

CRDF : 1.7900 (-0.56%)

Barchart Exclusives

Alphabet Stock Forecast: Can GOOGL Deliver Nearly 40% Gains in 12 Months? Barchart - 11 minutes ago
Robust growth in Search, accelerating cloud adoption, and expanding AI monetization provide a solid base for sustained revenue expansion. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.